The landscape of TIGIT target and clinical application in diseases

The landscape of TIGIT target and clinical application in diseases
复制标题

DOI:
10.1002/mog2.18
复制
发表时间:
2022-09
期刊:
MedComm – Oncology
影响因子:
--
通讯作者:
Shu Rui;Xiangyu Kong;Jiaye Liu;Liying Wang;Xiaofei Wang;X. Zou;Xun Zheng;Feng Ye;Heng Xu;Zhihui Li;Han Luo
Shu Rui;Xiangyu Kong;Jiaye Liu;Liying Wang;Xiaofei Wang;X. Zou;Xun Zheng;Feng Ye;Heng Xu;Zhihui Li;Han Luo
中科院分区:
其他
文献类型:
--
作者:
Shu Rui;Xiangyu Kong;Jiaye Liu;Liying Wang;Xiaofei Wang;X. Zou;Xun Zheng;Feng Ye;Heng Xu;Zhihui Li;Han Luo

文献摘要

相似文献

免疫检查点阻断在过去几年中极大地改变了癌症治疗的概念。除了现有的经典途径,近年来还出现了新的免疫检查点,如T细胞免疫球蛋白和基于免疫受体酪氨酸抑制基序(ITIM)结构域(TIGIT),并具有很好的治疗潜力。最近的研究提供了充分的证据表明,TIGIT广泛参与各种癌症和非癌症疾病,如慢性炎症,自身免疫性疾病,异常妊娠状态,以及最近的冠状病毒疾病2019。与主要影响T细胞功能的程序性细胞死亡受体1途径相反,靶向TIGIT途径调节多种类型的免疫细胞,但具有较少的免疫相关不良事件。由于其独特的优势和广泛的参与疾病,广泛的临床试验阻断TIGIT或联合收割机与其他目标正在进行中,许多II期临床试验已经看到了可喜的结果。本文综述了TIGIT在多种疾病中的研究进展,并对靶向治疗TIGIT的前景和挑战进行了探讨,以期为后续研究提供方向。
Immune checkpoint blockade has dramatically altered the concept of cancer therapeutics over the past few years. Beyond the existing classical pathways, novel immune checkpoints, such as T‐cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif (ITIM) structural domain (TIGIT), have also emerged in recent years and have promising therapeutic potential. Recent researches have provided ample evidence that TIGIT is extensively involved in various cancerous and noncancerous diseases such as chronic inflammation, autoimmune diseases, abnormal pregnancy status, and most recently coronavirus disease 2019. In contrast to the programmed cell death receptor 1 pathway which primarily affects T‐cell function, targeting TIGIT pathway regulates multiple types of immunocytes but has fewer immune‐related adverse events. Owing to its unique advantages and extensive involvement in diseases, extensive clinical trials blockade TIGIT or combine it with other targets are ongoing, and numerous phase II clinical trials have already seen promising results. In this review, we summarized the existing research on TIGIT in various diseases and discussed the perspective and challenges related to targeting this molecular for therapy, with an attempt to provide directions for subsequent studies.